Title

FRONTIER

Chief Investigator: 

An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer

This pre-operative observational imaging study will characterise the uptake of Fluciclovine 18F-FACBC on PET imaging in different breast cancer subtypes and correlate uptake with gene expression and metabolomic profile to form the basis of further work to investigate its potential uses. The study group will include up to 45 participants recruited from the Churchill Hospital in Oxford. Participants will be post-menopausal women with histologically proven breast cancer measuring ≥ 2cm scheduled to be treated by primary surgical resection. All participants will undergo fluciclovine (18F) PET/CT of the breast tumour before surgery, and breast tumour sample collection during surgery. Fluciclovine (18F) uptake by the tumour will then be compared to the tumour receptor subtype and results of the tumour sample analyses.

The study opened in February 2017 and is scheduled to continue until August 2018.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.